THE RISE OF NEW TECHNOLOGIES FOR AORTIC VALVE STENOSIS: A PROPENSITY-SCORE ANALYSIS FROM TWO MULTICENTER REGISTRIES COMPARING SUTURELESS AND TRANS-CATHETER AORTIC VALVE REPLACEMENT. A. D’Onofrio, S. Salizzoni, A. Rubino, L. Besola, C. Filippini, O. Alfieri, A. Colombo, M. Agrifoglio, T. Fischlein, F. Rapetto, G. Tarantini, M. Dalén, D. Gabbieri, B. Meuris, C. Savini, G. Gatti, M. Aiello, F. Biancari, U. Livi, P. Stefàno, M. Cassese, B. Borrello, M. Rinaldi, C. Mignosa and G. Gerosa. Padova, Torino, Catania, Milano, Nurnberg, Genova, Stockolm, Modena, Leuven, Bologna, Trieste, Pavia, Oulu, Udine, Firenze, Bari, Parma.
15
Embed
THE RISE OF NEW TECHNOLOGIES FOR AORTIC VALVE STENOSIS: A PROPENSITY-SCORE ANALYSIS FROM TWO MULTICENTER REGISTRIES COMPARING SUTURELESS AND TRANS-CATHETER.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
THE RISE OF NEW TECHNOLOGIES FOR AORTIC VALVE STENOSIS: A PROPENSITY-SCORE ANALYSIS FROM TWO MULTICENTER REGISTRIES COMPARING SUTURELESS AND TRANS-CATHETER AORTIC VALVE REPLACEMENT.
A. D’Onofrio, S. Salizzoni, A. Rubino, L. Besola, C. Filippini, O. Alfieri, A. Colombo, M. Agrifoglio, T. Fischlein, F. Rapetto, G. Tarantini, M. Dalén, D. Gabbieri, B. Meuris, C. Savini, G. Gatti, M. Aiello, F. Biancari, U. Livi, P. Stefàno, M. Cassese, B. Borrello, M. Rinaldi, C. Mignosa and G. Gerosa.
Dr. Augusto D’Onofrio is a physician proctor for Edwards Lifesciences
Background and aim
According to recent data, TAVR and SU-AVR may be both considered reliable alternative approaches to surgical AVR for the treatment of patients with aortic valve disease
The aim of this retrospective multicenter study was to compare early outcomes of TAVR and SU-AVR in patients with severe aortic valve stenosis.
Patients and Methods - TAVR
ITalian balloon-Expandable Registry (ITER) 2007-2012 Sapien/Sapien XT TA/TF 33 Italian Institutions
Patients and Methods – SU-AVR
European SU-AVR study group 2010-2014 Perceval S 6 European Institutions
Catania, Nurnberg, Stockolm, Oulu, Leuven, Trieste
Propensity matching 1:1 Age
Sex
Diabetes
Extra cardiac artery disease
Chronic lung disease
Previous cardiac surgery
Renal impairment
Pulmonary hypertension
Left ventricular ejection fraction
Body mass index
History of coronary artery disease (defined as previous coronary intervention or bypass grafting at the time of intervention)
• All TAVR vs. SU-AVR
• TA-TAVR vs. SU-AVR
• TF-TAVR vs. SU-AVR
Endpoints Primary endpoint
Evaluation of the following outcomes 30 days after the index procedure (according to VARC-2) All-cause mortality Device success Any stroke Bleeding (life-threating or major) Pace-maker AMI Paravalvular leaks
Secondary endpoint Evaluation at discharge of:
Peak and mean gradients LVEF Hours of intubation ICU Length of stay In-hospital Length of stay